Hemab Presents Sutacimig Data; Wedbush Rates Outperform, $55 Target

Hemab Therapeutics presented new clinical and preclinical data for lead candidate Sutacimig at the ISTH 2026 Congress in Paris, highlighting potential to improve treatment for Glanzmann thrombasthe. The update is development-stage and supportive, but with no reported efficacy/safety figures in the article, so it is unlikely to materially move markets on its own.

Analysis

Hemab Therapeutics presented new clinical and preclinical data for lead candidate Sutacimig at the ISTH 2026 Congress in Paris, highlighting potential to improve treatment for Glanzmann thrombasthe. The update is development-stage and supportive, but with no reported efficacy/safety figures in the article, so it is unlikely to materially move markets on its own.